Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3201-3210 Newer>

Bio-IT World October 2006 Thomas G. Morr	Eight Essential Elements for Commercial Success For life sciences companies both young and old, location is one of the critical success factors. With that in mind, here are eight essential considerations for life sciences executives when they are thinking of starting a business or opening a new location.
Bio-IT World October 2006 Kevin Davies	Cracking the Cancer Genome Regardless of which technologies win out, or which centers win the lucrative sequencing contracts, the Cancer Genome Atlas has a sublime medical and scientific importance, underscored by the latest findings from Hopkins.
Bio-IT World October 2006 John Russell	Sweetening the Swiss Bio Mix Switzerland is now attempting to become a power throughout the entire life science food chain - from basic research to small and big business.
The Motley Fool October 17, 2006 Brian Lawler	Lilly Doesn't Like Sharing Profits The company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis. Investors, take note.
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
Fast Company October 2006	Fast Talk: Medic! Lois Quam says our balky health-care system presents a "classic redesign challenge."
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool October 16, 2006 Brian Lawler	Bayer's Big Drug Boo-Boo The company's forgetfulness could end up hurting its reputation even worse than its revenues.
The Motley Fool October 16, 2006 Brian Lawler	MGI Drug Approval Falters The FDA gives the thumbs-down to Saforis. However, investors should take notice of this well-run pharmaceutical.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
<Older 3201-3210 Newer> Return to current articles.